{
    "id": 16284,
    "fullName": "HBEGF over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HBEGF over exp indicates an over expression of the Hbegf protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1839,
        "geneSymbol": "HBEGF",
        "terms": [
            "HBEGF",
            "DTR",
            "DTS",
            "DTSF",
            "HEGFL"
        ]
    },
    "variant": "over exp",
    "createDate": "01/09/2016",
    "updateDate": "07/06/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7608,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Iressa (gefitinib) and Tafinlar (dabrafenib) resulted in a synergistic effect in a non-small cell lung carcinoma cell line harboring BRAF V600E and over expressing HBEGF, demonstrating decreased colony formation in culture and tumor growth inhibition in xenograft models (PMID: 27196768).",
            "molecularProfile": {
                "id": 25917,
                "profileName": "BRAF V600E HBEGF over exp"
            },
            "therapy": {
                "id": 4524,
                "therapyName": "Dabrafenib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6442,
                    "pubMedId": 27196768,
                    "title": "EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7610,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring BRAF V600E and over expression of HBEGF demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 27196768).",
            "molecularProfile": {
                "id": 25917,
                "profileName": "BRAF V600E HBEGF over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6442,
                    "pubMedId": 27196768,
                    "title": "EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7611,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring BRAF V600E and over expression of HBEGF demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 27196768).",
            "molecularProfile": {
                "id": 25917,
                "profileName": "BRAF V600E HBEGF over exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6442,
                    "pubMedId": 27196768,
                    "title": "EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7609,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Tafinlar (dabrafenib) resulted in a synergistic effect in a non-small cell lung carcinoma cell line harboring BRAF V600E and over expressing HBEGF in culture, demonstrating decreased cell survival and inhibition of colony formation (PMID: 27196768).",
            "molecularProfile": {
                "id": 25917,
                "profileName": "BRAF V600E HBEGF over exp"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6442,
                    "pubMedId": 27196768,
                    "title": "EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7607,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring BRAF V600E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture due to upregulation of HBEGF, which resulted in activation of EGFR and subsequent Erk signaling (PMID: 27196768).",
            "molecularProfile": {
                "id": 25917,
                "profileName": "BRAF V600E HBEGF over exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6442,
                    "pubMedId": 27196768,
                    "title": "EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17214,
            "profileName": "HBEGF over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25917,
            "profileName": "BRAF V600E HBEGF over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}